Equities

Atara Biotherapeutics Inc

Atara Biotherapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)11.67
  • Today's Change-0.10 / -0.85%
  • Shares traded107.91k
  • 1 Year change+103.13%
  • Beta0.5321
Data delayed at least 15 minutes, as of Nov 12 2024 21:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform4
Hold2
Sell1
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Atara Biotherapeutics Inc have a median target of 10.00, with a high estimate of 18.00 and a low estimate of 9.00. The median estimate represents a -14.31% decrease from the last price of 11.67.
High54.2%18.00
Med-14.3%10.00
Low-22.9%9.00

Earnings history & estimates in USD

On Nov 12, 2024, Atara Biotherapeutics Inc reported 3rd quarter 2024 losses of -2.93 per share.
The next earnings announcement is expected on Mar 06, 2025.
Average growth rate+31.41%
Atara Biotherapeutics Inc reported annual 2023 losses of -65.25 per share on Mar 28, 2024.
Average growth rate+15.28%
More ▼

Revenue history & estimates in USD

Atara Biotherapeutics, Inc. had 3rd quarter 2024 revenues of 40.19m. This bettered the 35.17m consensus of the 5 analysts covering the company. This was 3,178.14% above the prior year's 3rd quarter results.
Average growth rate+171.82%
Atara Biotherapeutics, Inc. had revenues for the full year 2023 of 8.57m. This was 86.51% below the prior year's results.
Average growth rate+42.01%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.